{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:07:57Z","timestamp":1776092877169,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>Vincristine is a widely used chemotherapeutic agent in the treatment of childhood malignancies. Neuropathy is the most common adverse effect. CYP3A4 and CYP3A5 enzymes of cytochrome p450 enzyme system are responsible in vincristine metabolism. Genetic polymorphism may alter the vincristine metabolism and the neurotoxicity rate. In this study, distribution of CYP3A5 alleles among Turkish children with malignancies, relation between CYP3A5 genotype and neurotoxicity rates, as well as severity and duration of neuropathy and total vincristine doses were investigated. Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols. Control group consisted of 50 children without any neurological symptom or disorders. All patient files were reviewed for presence and severeness of neurotoxicity symptoms. Blood samples were obtained and CYP3A5 genotypes were analyzed. Neurotoxicity occurred in 20.8% of patients. Although it was found to occur more frequently after 4 doses of vincristine, and rates were higher in the low-dose vincristine group suggesting other contributing factors. Although neurotoxicity rate in the CYP3A5*1\/*3 genotype was 17.6%, it was 21.6% in the CYP3A5*3\/*3 genotype and the difference was not statistically significant (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.05). This study suggested that vincristine-related neurotoxicity is dose-independent and genotype is not the only causative factor in the occurrence of neurotoxicity in these patients.<\/jats:p>","DOI":"10.1097\/mph.0000000000000910","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T14:26:28Z","timestamp":1499783188000},"page":"458-462","source":"Crossref","is-referenced-by-count":15,"title":["Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population"],"prefix":"10.1097","volume":"39","author":[{"given":"H\u00fclya","family":"Kayilio\u011flu","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulker","family":"Kocak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Kan Karaer","sequence":"additional","affiliation":[{"name":"Department of Genetics, Gazi University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emriye F.","family":"Percin","sequence":"additional","affiliation":[{"name":"Department of Genetics, Gazi University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertan","family":"Sal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Tekkesin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melek","family":"Isik","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nergiz","family":"Oner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma B.","family":"Belen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru","family":"Yilmaz Keskin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu","family":"Okur","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Albayrak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Kirikkale University School of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuhre","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faruk G.","family":"Pinarli","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idil","family":"Yenicesu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceyda","family":"Karadeniz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aynur","family":"Oguz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turkiz","family":"Gursel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00520-010-1043-2","article-title":"Burden of chemotherapy-induced neuropathy\u2014a cross-sectional study","volume":"19","author":"Kautio","year":"2011","journal-title":"Support Care Cancer"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1023\/A:1008345613594","article-title":"Grading of chemotherapy-induced peripheral neuropathy","volume":"11","author":"Postma","year":"2000","journal-title":"Ann Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/08880018.2011.629859","article-title":"ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia\u2014experience of a single center","volume":"29","author":"Kocak","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pbc.21435","article-title":"Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients","volume":"50","author":"Renbarger","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/phgs.5.3.243.29833","article-title":"Genetic variability in CYP3A5 and its possible consequences","volume":"5","author":"Xie","year":"2004","journal-title":"Pharmacogenomics"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.leukres.2009.04.027","article-title":"Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia","volume":"34","author":"Hartman","year":"2010","journal-title":"Leuk Res"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1529-8027.2009.00230.x","article-title":"Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia","volume":"14","author":"Ramchandren","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1008348010437","article-title":"Liposomal vincristine in relapsed non-Hodgkin\u2019s lymphomas: early results of an ongoing phase II trial","volume":"11","author":"Sarris","year":"2000","journal-title":"Ann Oncol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0883073813491829","article-title":"Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics","volume":"29","author":"Jain","year":"2013","journal-title":"J Child Neurol"},{"key":"R16-20230918","first-page":"1","article-title":"Acute and long-term neurologic complications in children with acute lymphoblastic leukemia","volume":"48","author":"Aytac","year":"2006","journal-title":"Turk J Pediatr"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155214553143","article-title":"The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia","volume":"22","author":"Sims","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0883073811428379","article-title":"Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia","volume":"27","author":"Brigo","year":"2012","journal-title":"J Child Neurol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"key":"R21-20230918","first-page":"619","article-title":"Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies","volume":"12","author":"Ocean","year":"2004","journal-title":"Support Care Cancer"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/pbc.23039","article-title":"Neuropathic pain during treatment for childhood acute lymphoblastic leukemia","volume":"57","author":"Anghelescu","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clbc.2011.03.006","article-title":"Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach","volume":"11","author":"Carlson","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12098-009-0254-3","article-title":"Vincristine induced neurotoxicity in cancer patients","volume":"77","author":"Gomber","year":"2010","journal-title":"Indian J Pediatr"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jnnp.32.4.297","article-title":"Vincristine neuropathy: an electrophysiological and histological study","volume":"32","author":"McLeod","year":"1969","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pediatrneurol.2009.07.005","article-title":"Vincristine-induced unilateral ptosis in a child","volume":"41","author":"Gursel","year":"2009","journal-title":"Pediatr Neurol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201708000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:09:28Z","timestamp":1695010168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201708000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000910","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}